Timber Hill LLC bought a new stake in Boston Scientific Co. (NYSE:BSX) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 53,191 shares of the medical equipment provider’s stock, valued at approximately $1,319,000.
A number of other institutional investors also recently added to or reduced their stakes in the stock. Edgestream Partners L.P. purchased a new stake in Boston Scientific in the fourth quarter valued at approximately $285,000. Citizens Financial Group Inc RI grew its holdings in Boston Scientific by 2.7% in the fourth quarter. Citizens Financial Group Inc RI now owns 238,537 shares of the medical equipment provider’s stock valued at $5,913,000 after purchasing an additional 6,237 shares during the period. Norinchukin Bank The grew its holdings in Boston Scientific by 7.5% in the fourth quarter. Norinchukin Bank The now owns 109,790 shares of the medical equipment provider’s stock valued at $2,722,000 after purchasing an additional 7,662 shares during the period. Ontario Teachers Pension Plan Board grew its holdings in Boston Scientific by 5.1% in the fourth quarter. Ontario Teachers Pension Plan Board now owns 286,210 shares of the medical equipment provider’s stock valued at $7,095,000 after purchasing an additional 13,839 shares during the period. Finally, American International Group Inc. grew its holdings in Boston Scientific by 4.2% in the fourth quarter. American International Group Inc. now owns 426,401 shares of the medical equipment provider’s stock valued at $10,570,000 after purchasing an additional 17,299 shares during the period. Hedge funds and other institutional investors own 87.77% of the company’s stock.
In other news, SVP Maulik Nanavaty sold 15,568 shares of the business’s stock in a transaction on Friday, February 9th. The shares were sold at an average price of $25.38, for a total transaction of $395,115.84. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP David A. Pierce sold 8,763 shares of the business’s stock in a transaction on Thursday, January 11th. The stock was sold at an average price of $27.74, for a total transaction of $243,085.62. Following the transaction, the senior vice president now directly owns 24,201 shares in the company, valued at $671,335.74. The disclosure for this sale can be found here. Over the last three months, insiders have sold 177,032 shares of company stock worth $4,648,733. Corporate insiders own 0.74% of the company’s stock.
Boston Scientific Co. (BSX) opened at $26.77 on Thursday. Boston Scientific Co. has a 12-month low of $23.29 and a 12-month high of $29.93. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.50 and a current ratio of 0.72. The company has a market cap of $36,888.86, a price-to-earnings ratio of 382.43, a PEG ratio of 1.95 and a beta of 0.81.
Boston Scientific (NYSE:BSX) last posted its earnings results on Thursday, February 1st. The medical equipment provider reported $0.34 EPS for the quarter, hitting analysts’ consensus estimates of $0.34. Boston Scientific had a net margin of 1.15% and a return on equity of 24.04%. The business had revenue of $2.41 billion for the quarter, compared to analysts’ expectations of $2.39 billion. During the same period in the previous year, the company posted $0.30 earnings per share. The business’s revenue for the quarter was up 9.9% compared to the same quarter last year. research analysts anticipate that Boston Scientific Co. will post 1.37 EPS for the current year.
BSX has been the subject of a number of recent analyst reports. Zacks Investment Research downgraded shares of Boston Scientific from a “hold” rating to a “sell” rating in a report on Tuesday, January 9th. TheStreet downgraded shares of Boston Scientific from a “b” rating to a “c+” rating in a report on Thursday, December 7th. BMO Capital Markets reaffirmed a “buy” rating and set a $32.00 price target on shares of Boston Scientific in a research report on Tuesday, December 12th. Canaccord Genuity reduced their price target on shares of Boston Scientific from $36.00 to $35.00 and set a “buy” rating on the stock in a research report on Wednesday, November 29th. Finally, JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Boston Scientific in a research report on Wednesday, November 29th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Boston Scientific currently has an average rating of “Buy” and a consensus target price of $31.00.
WARNING: “Timber Hill LLC Buys New Holdings in Boston Scientific Co. (BSX)” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another publication, it was stolen and republished in violation of United States & international trademark and copyright laws. The correct version of this piece can be read at https://www.dispatchtribunal.com/2018/02/22/timber-hill-llc-buys-new-holdings-in-boston-scientific-co-bsx.html.
Boston Scientific Profile
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.
Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSX).
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.